‘Zombie’ Biotech Buyer Xoma to Acquire Generation Bio

‘Zombie’ biotech buyer Xoma to acquire Generation Bio

The gene therapy developer has lost most of its value since going public in 2020 and saw a long road ahead for a delivery technology that had shown promise in preclinical tests.

‘Zombie’ biotech buyer Xoma to acquire Generation Bio – RamaOnHealthcare

The gene therapy developer has lost most of its value since going public in 2020 and saw a long road ahead for a delivery technology that had shown promise in preclinical tests.Xoma Royalty, which has recently built a business out of acquiring struggling biotechnology companies, has secured its latest target.In announcement late Monday, Xoma said [...]

Shareholder Alert: The Ademi Firm investigates whether Generation Bio Co. is obtaining a Fair Price for its Public Shareholders

MILWAUKEE, Dec. 15, 2025 /PRNewswire/ -- The Ademi Firm is investigating Generation Bio (Nasdaq: GBIO) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with XOMA Royalty Corporation.

XOMA Royalty to Acquire Generation Bio

EMERYVILLE, Calif. and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) — XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has entered into an agreement to acquire Generation Bio Co. (NASDAQ: GBIO) for a cash price of $4.2913 per share at the closing of the merger. Generation Bio stockholders also will receive one non-transferable contingent value right (“CVR”) per share that entitles holders to receive…